Antibody Titers Before and After a Third Dose of the SARS-CoV-2 BNT162b2 Vaccine in Adults Aged ≥60 Years

doi:10.1001/jama.2021.19885

. 2021 Dec 7;326(21):2203-2204.

doi: 10.1001/jama.2021.19885.

Antibody Titers Before and After a Third Dose of the SARS-CoV-2 BNT162b2 Vaccine in Adults Aged ≥60 Years

Noa Eliakim-Raz¹, Yaara Leibovici-Weisman¹, Amos Stemmer², Asaf Ness¹, Muhammad Awwad¹, Nassem Ghantous¹, Salomon M Stemmer¹

Affiliations

¹ Rabin Medical Center, Tel Aviv University Sackler School of Medicine, Tel Aviv, Israel.
² Department of Oncology, Sheba Medical Center, Tel Hashomer, Israel.

PMID: 34739043
PMCID: PMC8652594
DOI: 10.1001/jama.2021.19885

Antibody Titers Before and After a Third Dose of the SARS-CoV-2 BNT162b2 Vaccine in Adults Aged ≥60 Years

Noa Eliakim-Raz et al. JAMA. 2021.

. 2021 Dec 7;326(21):2203-2204.

doi: 10.1001/jama.2021.19885.

Authors

Noa Eliakim-Raz¹, Yaara Leibovici-Weisman¹, Amos Stemmer², Asaf Ness¹, Muhammad Awwad¹, Nassem Ghantous¹, Salomon M Stemmer¹

Affiliations

¹ Rabin Medical Center, Tel Aviv University Sackler School of Medicine, Tel Aviv, Israel.
² Department of Oncology, Sheba Medical Center, Tel Hashomer, Israel.

PMID: 34739043
PMCID: PMC8652594
DOI: 10.1001/jama.2021.19885

Abstract

This study assesses antispike (anti-S) IgG antibody titers before and after a third BNT162b2 dose (booster) in individuals aged 60 years and older in Israel.

PubMed Disclaimer

Conflict of interest statement

Conflict of Interest Disclosures: Dr S. M. Stemmer reported receiving research grants (to his institution) from CAN-FITE, AstraZeneca, BioLineRX, BMS, Clovis Oncology, CTG Pharma, Exelixis, GEICAM, Halozyme, Incyte, Lilly, Moderna, Teva Pharmaceuticals, and Roche and owning stocks and options in CTG Pharma, DocBoxMD, TyrNovo, VYPE, Cytora, and CAN-FITE. No other disclosures were reported.

Cited by

Demographic and Clinical Factors Associated With SARS-CoV-2 Spike 1 Antibody Response Among Vaccinated US Adults: the C4R Study.
Kim JS, Sun Y, Balte P, Cushman M, Boyle R, Tracy RP, Styer LM, Bell TD, Anderson MR, Allen NB, Schreiner PJ, Bowler RP, Schwartz DA, Lee JS, Xanthakis V, Doyle MF, Regan EA, Make BJ, Kanaya AM, Wenzel SE, Coresh J, Isasi CR, Raffield LM, Elkind MSV, Howard VJ, Ortega VE, Woodruff P, Cole SA, Henderson JM, Mantis NJ, Parker MM, Demmer RT, Oelsner EC. Kim JS, et al. Nat Commun. 2024 Feb 19;15(1):1492. doi: 10.1038/s41467-024-45468-9. Nat Commun. 2024. PMID: 38374032 Free PMC article.
Dynamics of Anti-SARS-CoV-2 IgA and IgG Responses and Their Protective Effect against Fatal Disease after Booster COVID-19 Vaccination.
Speletas M, Voulgaridi I, Bogogiannidou Z, Sarrou S, Kyritsi MA, Theodoridou A, Dadouli K, Matziri A, Vontas A, Pappa D, Konstantinou AK, Tsigalou C, Kalala F, Mouchtouri VA, Hadjichristodoulou C. Speletas M, et al. Vaccines (Basel). 2023 Dec 21;12(1):12. doi: 10.3390/vaccines12010012. Vaccines (Basel). 2023. PMID: 38276671 Free PMC article.
Humoral and Cellular Immune Responses of People Living With Human Immunodeficiency Virus After 3 Doses of Messenger RNA BNT162b2 Severe Acute Respiratory Syndrome Coronavirus 2 Vaccine: A Prospective Cohort Study.
Tau L, Hagin D, Freund T, Halperin T, Adler A, Marom R, Ahsanov S, Matus N, Levi I, Gerber G, Lev S, Ziv-Baran T, Turner D. Tau L, et al. Open Forum Infect Dis. 2023 Jul 10;10(8):ofad347. doi: 10.1093/ofid/ofad347. eCollection 2023 Aug. Open Forum Infect Dis. 2023. PMID: 37539062 Free PMC article.
Longitudinal study of humoral immunity against SARS-CoV-2 of health professionals in Brazil: the impact of booster dose and reinfection on antibody dynamics.
Franco-Luiz APM, Fernandes NMGS, Silva TBS, Bernardes WPOS, Westin MR, Santos TG, Fernandes GDR, Simões TC, Silva EFE, Gava SG, Alves BM, de Carvalho Melo M, da Silva-Pereira RA, Alves PA, Fonseca CT. Franco-Luiz APM, et al. Front Immunol. 2023 Jul 14;14:1220600. doi: 10.3389/fimmu.2023.1220600. eCollection 2023. Front Immunol. 2023. PMID: 37520570 Free PMC article.
Serologic Response and Safety after a Third Dose of the COVID-19 BNT162b2 Vaccine in Patients with Inflammatory Bowel Diseases.
Edelman-Klapper H, Rabinowitz KM, Zittan E, Bar-Gil Shitrit A, Goren I, Avni-Biron I, Ollech JE, Lichtenstein L, Banai-Eran H, Yanai H, Snir Y, Pauker MH, Friedenberg A, Levy-Barda A, Broitman Y, Ben Zvi H, Perets TT, Eliakim R, Barkan R, Goren S, Cohen D, Dotan I; REsponses to COVid-19 vaccinE IsRaeli IBD group [RECOVERI]. Edelman-Klapper H, et al. Vaccines (Basel). 2023 Jul 20;11(7):1263. doi: 10.3390/vaccines11071263. Vaccines (Basel). 2023. PMID: 37515078 Free PMC article.

See all "Cited by" articles

References

1. Walsh EE, Frenck RW Jr, Falsey AR, et al. . Safety and immunogenicity of two RNA-based Covid-19 vaccine candidates. N Engl J Med. 2020;383(25):2439-2450. doi:10.1056/NEJMoa2027906 - DOI - PMC - PubMed
1. Levin EG, Lustig Y, Cohen C, et al. . Waning immune humoral response to BNT162b2 Covid-19 vaccine over 6 months. N Engl J Med. Published online October 6, 2021. doi:10.1056/NEJMoa2114583 - DOI - PMC - PubMed
1. Benotmane I, Gautier G, Perrin P, et al. . Antibody response after a third dose of the MRNA-1273 SARS-CoV-2 vaccine in kidney transplant recipients with minimal serologic response to 2 doses. JAMA. 2021;326(11):1063-1065. doi:10.1001/jama.2021.12339 - DOI - PMC - PubMed
1. Bar-On YM, Goldberg Y, Mandel M, et al. . Protection of BNT162b2 vaccine booster against Covid-19 in Israel. N Engl J Med. 2021;385(15):1393-1400. doi:10.1056/NEJMoa2114255 - DOI - PMC - PubMed
1. Harvey RA, Rassen JA, Kabelac CA, et al. . Association of SARS-CoV-2 seropositive antibody test with risk of future infection. JAMA Intern Med. 2021;181(5):672-679. doi:10.1001/jamainternmed.2021.0366 - DOI - PMC - PubMed

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions
Actions
Actions
Actions
Actions

LinkOut - more resources

Full Text Sources
Medical
- MedlinePlus Health Information
Miscellaneous
- NCI CPTAC Assay Portal

[1] Walsh EE, Frenck RW Jr, Falsey AR, et al. . Safety and immunogenicity of two RNA-based Covid-19 vaccine candidates. N Engl J Med. 2020;383(25):2439-2450. doi:10.1056/NEJMoa2027906 - DOI - PMC - PubMed

[2] Walsh EE, Frenck RW Jr, Falsey AR, et al. . Safety and immunogenicity of two RNA-based Covid-19 vaccine candidates. N Engl J Med. 2020;383(25):2439-2450. doi:10.1056/NEJMoa2027906 - DOI - PMC - PubMed

[3] Levin EG, Lustig Y, Cohen C, et al. . Waning immune humoral response to BNT162b2 Covid-19 vaccine over 6 months. N Engl J Med. Published online October 6, 2021. doi:10.1056/NEJMoa2114583 - DOI - PMC - PubMed

[4] Levin EG, Lustig Y, Cohen C, et al. . Waning immune humoral response to BNT162b2 Covid-19 vaccine over 6 months. N Engl J Med. Published online October 6, 2021. doi:10.1056/NEJMoa2114583 - DOI - PMC - PubMed

[5] Benotmane I, Gautier G, Perrin P, et al. . Antibody response after a third dose of the MRNA-1273 SARS-CoV-2 vaccine in kidney transplant recipients with minimal serologic response to 2 doses. JAMA. 2021;326(11):1063-1065. doi:10.1001/jama.2021.12339 - DOI - PMC - PubMed

[6] Benotmane I, Gautier G, Perrin P, et al. . Antibody response after a third dose of the MRNA-1273 SARS-CoV-2 vaccine in kidney transplant recipients with minimal serologic response to 2 doses. JAMA. 2021;326(11):1063-1065. doi:10.1001/jama.2021.12339 - DOI - PMC - PubMed

[7] Bar-On YM, Goldberg Y, Mandel M, et al. . Protection of BNT162b2 vaccine booster against Covid-19 in Israel. N Engl J Med. 2021;385(15):1393-1400. doi:10.1056/NEJMoa2114255 - DOI - PMC - PubMed

[8] Bar-On YM, Goldberg Y, Mandel M, et al. . Protection of BNT162b2 vaccine booster against Covid-19 in Israel. N Engl J Med. 2021;385(15):1393-1400. doi:10.1056/NEJMoa2114255 - DOI - PMC - PubMed

[9] Harvey RA, Rassen JA, Kabelac CA, et al. . Association of SARS-CoV-2 seropositive antibody test with risk of future infection. JAMA Intern Med. 2021;181(5):672-679. doi:10.1001/jamainternmed.2021.0366 - DOI - PMC - PubMed

[10] Harvey RA, Rassen JA, Kabelac CA, et al. . Association of SARS-CoV-2 seropositive antibody test with risk of future infection. JAMA Intern Med. 2021;181(5):672-679. doi:10.1001/jamainternmed.2021.0366 - DOI - PMC - PubMed

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Antibody Titers Before and After a Third Dose of the SARS-CoV-2 BNT162b2 Vaccine in Adults Aged ≥60 Years

Affiliations

Antibody Titers Before and After a Third Dose of the SARS-CoV-2 BNT162b2 Vaccine in Adults Aged ≥60 Years

Authors

Affiliations

Abstract

Conflict of interest statement

Similar articles

Cited by

References

MeSH terms

Substances

LinkOut - more resources

Full Text Sources

Medical

Miscellaneous

Abstract

Conflict of interest statement

Similar articles

Cited by

References

MeSH terms

Substances

Related information

LinkOut - more resources

Full Text Sources

Medical

Miscellaneous